Chad Tang: Sequential SBRT for Oligometastatic Clear Cell RCC
Chad Tang, Radiation Oncologist at the MD Anderson Cancer Center, shared a post on X:
“Excited to share our recent Lancet Oncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases.
This phase II expansion cohort came on the heals of our original 2021 manuscript demonstrating the feasibility of SBRT alone. We expanded our trial and pre-specified a 2 year systemic therapy survival as our threshold for success.
After a median of 3 year follow up. The median systemic therapy free survival was 34 months exceeding our threshold for success. PFS was promising as well with median 17.7 months.
We looked at ctDNA using the myriad 2nd generation assay and found 60% of patients to exhibit molecular residual disease. Furthermore this marker was highly prognostic both before and after radiation therapy.
So med oncologists, I know we need randomized phase 3 data but hopefully we can consider this treatment for low volume patients.”
Title: Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial
Authors: Chad Tang, Alexander D. Sherry, Aaron Seo, Kieko Hara, Haesun Choi, Suyu Liu, Xiaowen Sun, Anya Montoya, Ethan B. Ludmir, Amishi Y. Shah, Eric Jonasch, Amado J. Zurita, Craig Kovitz, Omar Alhalabi, Sangeeta Goswami, Andrew W. Hahn, Matthew T. Campbell, Arianna Hernandez, Kevin T. Nead, Peter Van Loo, Pavlos Msaouel
Read The Full Article at The Lancet Oncology.
More Posts Featuring Renal Cell Carcinoma.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023